Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 340 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "levodopa" Clear all
Suspended Phase 1Phase 2 Interventional

Microbiota Intervention to Change the Response of Parkinson's Disease

NCT03575195
View directory record Official record
Conditions
Parkinson Disease
Interventions
Rifaximin, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 23, 2026, 4:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Parkinsonism in Spinocerebellar Ataxia Type 6

NCT01934998
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 6
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

KW-6002 to Treat Parkinson's Disease

NCT00006337
View directory record Official record
Conditions
Parkinson's Disease
Interventions
KW-6002, IV Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 4:23 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

NCT02153645
View directory record Official record
Conditions
Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Interventions
240mg Amantadine HCl ER tablets, Placebo tablets, 320mg Amantadine HCl ER tablets
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Not applicable Interventional

Identification of Clinically Relevant Markers of Deep Brain Stimulation Electrode Impedance

NCT02794233
View directory record Official record
Conditions
Parkinson Disease
Interventions
Impedance measurements
Other
Lead sponsor
University of Florida
Other
Eligibility
25 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 23, 2026, 4:23 PM EDT
Completed No phase listed Observational

Opicapone Treatment Initiation Open-Label Study

NCT04787965
View directory record Official record
Conditions
Parkinson Disease
Interventions
Opicapone
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Los Gatos, California • Memphis, Tennessee • Christiansburg, Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Jul 23, 2026, 4:23 PM EDT
Recruiting Phase 1 Interventional

Diagnosis of Pheochromocytoma

NCT00004847
View directory record Official record
Conditions
Pheochromocytoma, Endocrine Disease, Endocrine Diseases
Interventions
([18F]-DOPA), ([18F]-6F-DA)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 120 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2048
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of a Pre-Workout Dietary Supplement

NCT02952014
View directory record Official record
Conditions
Dietary Modification
Interventions
C4 Extreme, C4 Extreme (without Advantra Z, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

NCT00601523
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Sun City, Arizona • Tempe, Arizona • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

NCT02271503
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CD-LD IR, IPX203 180 mg, IPX203 270 mg, Rytary 195 mg, Rytary 145 mg
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse

NCT02080819
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa/carbidopa 400/100 BID
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 50 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Jul 23, 2026, 4:23 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of Using Vibrotactile Coordinated Reset for Management of Parkinson's Disease

NCT03857867
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tactile Stimulation Glove
Device
Lead sponsor
Peter Tass, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Jul 23, 2026, 4:23 PM EDT
Completed No phase listed Observational

Development of an Instrumented System to Measure Mobility in Parkinson's Disease

NCT01174758
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Jul 23, 2026, 4:23 PM EDT
Completed No phase listed Observational Results available

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

NCT03647137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Detailed motor testing, including FoG, in PD subjects
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treating Bacterial Overgrowth in Parkinson's Disease

NCT02470780
View directory record Official record
Conditions
Parkinson's Disease, Small Intestinal Bacterial Overgrowth
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Jul 23, 2026, 4:23 PM EDT
Recruiting Not applicable Interventional

Real-Time Levodopa Level Monitoring in Parkinson Disease

NCT04735627
View directory record Official record
Conditions
Parkinson Disease
Interventions
Levodopameter
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Jul 23, 2026, 4:23 PM EDT
Recruiting Phase 4 Interventional

Personalized Real-Time DBS and PD Mechanisms

NCT06013956
View directory record Official record
Conditions
Parkinson Disease
Interventions
Neurostimulation, Carbidopa 25/Levodopa 100Mg Tab
Device · Drug
Lead sponsor
David Escobar
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

NCT00253084
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX054 200 mg, CD-LD IR, IPX054 Placebo, CD-LD IR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

NCT06055985
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, UCB0022
Other · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
35 Years to 85 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
61
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

NCT05543252
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Minzasolmin (UCB0599)
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 78 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
41
States / cities
Phoenix, Arizona • Fountain Valley, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01385592
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Sunnyvale, California • Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jul 23, 2026, 4:23 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)

NCT00634556
View directory record Official record
Conditions
Tourette Syndrome
Interventions
levodopa solution 2mg/ml for i.v. use, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Jul 23, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01173731
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jul 23, 2026, 4:23 PM EDT